Trial intelligence / Profile preview

Hydroxychloroquine for adult outpatients with PCR-confirmed COVID-19

2020-002038-33Phase 2Terminated

Sponsor
Porin kaupunki
Start
Jun 2020
Modality
Small Molecules
Countries
1
01

Overview

Phase 2 trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Porin kaupunki. Primary endpoint: Hospitalizations due to COVID-19 infection within four weeks. Started Jun 2020; status: terminated.

02

Drugs

hydroxychloroquine
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on 2020-002038-33.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-002038-33.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call